Found: 5
Select item for more details and to access through your institution.
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma.
- Published in:
- Journal of Hematology & Oncology, 2024, v. 17, n. 1, p. 1, doi. 10.1186/s13045-024-01594-x
- By:
- Publication type:
- Article
Clinical and economic burden of regularly transfused adult patients with β‐thalassemia in the United States: A retrospective cohort study using payer claims.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 5, p. E129, doi. 10.1002/ajh.25429
- By:
- Publication type:
- Article
Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 3, p. 1226, doi. 10.1007/s12325-023-02775-9
- By:
- Publication type:
- Article
Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 9, p. 4659, doi. 10.1007/s12325-021-01838-z
- By:
- Publication type:
- Article
Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.
- Published in:
- 2021
- By:
- Publication type:
- journal article